Spots Global Cancer Trial Database for graft versus host disease
Every month we try and update this database with for graft versus host disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation | NCT00003056 | Leukemia Lymphoma Graft Versus Ho... | cyclosporine cyclosporine an... | 18 Years - 55 Years | Takeda | |
| Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation | NCT00189488 | Graft Versus Ho... Hematologic Mal... | Palifermin Placebo Conditioning Re... Allogeneic stem... Methotrexate | 18 Years - | Swedish Orphan Biovitrum | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | NCT01025778 | Acute Lymphobla... Acute Myeloid L... | Clofarabine for... Etoposide for r... Cyclophosphamid... Clofarabine in ... Thiotepa in con... Melfalan in con... Haploidentical ... Donor lymphocyt... | 1 Year - 21 Years | Lund University Hospital | |
| Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant | NCT00003894 | Graft Versus Ho... Unspecified Adu... Unspecified Chi... | thalidomide | 3 Years - | Roswell Park Cancer Institute | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals | NCT05655546 | Immunodeficienc... Immunosuppressi... HIV Infections Graft Versus Ho... Leukemia Lymphoma Cancer Multiple Myelom... Transplant Age-Related Imm... | Access to Cue H... | 18 Years - 120 Years | Scripps Translational Science Institute | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT) | NCT03419078 | Allogeneic Stem... Graft Versus Ho... Hematologic Mal... Stem Cell Trans... | 17 Years - | Imperial College Healthcare NHS Trust | ||
| Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | NCT00133367 | Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... Myelogenous Leu... Lymphoblastic L... | Tacrolimus Sirolimus G-CSF Antithymocyte g... Thymoglobulin Fludarabine Melphalan | 18 Years - 65 Years | Massachusetts General Hospital | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT | NCT03066466 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... | Atorvastatin Methotrexate Tacrolimus | 18 Years - 75 Years | Loyola University | |
| Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD | NCT00914940 | Graft Versus Ho... Leukemia Myelodysplastic... | Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted... | 14 Years - 55 Years | Fred Hutchinson Cancer Center | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Bone Marrow-derived Cells' Contribution to Tumor Formation and Inflammation | NCT00452205 | Gastrointestina... | 20 Years - 70 Years | Komagome Hospital | ||
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | NCT02258490 | Chronic Myeloid... Myelodysplastic... Acute Myeloid L... | G-CSF mobilized... | 17 Years - 75 Years | Emory University | |
| Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | NCT02500550 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | ATIR101 Haploidentical ... TBI regime Non-TBI regime | 18 Years - 65 Years | Kiadis Pharma | |
| Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin | NCT00822770 | Stem Cell Trans... Leukemia | Plerixafor Filgrastim Fludarabine Busulfan Allogeneic bloo... ATG (Thymoglobu... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation | NCT00720629 | Graft Versus Ho... | Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate | 18 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer | NCT00003661 | Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma | anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - 54 Years | Roswell Park Cancer Institute | |
| Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC | |
| Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | NCT02258490 | Chronic Myeloid... Myelodysplastic... Acute Myeloid L... | G-CSF mobilized... | 17 Years - 75 Years | Emory University | |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease | NCT01174940 | Stem Cell Leuke... Graft Versus Ho... | extracorporeal ... | 18 Years - | University of Kansas Medical Center | |
| Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT00093587 | Graft Versus Ho... Leukemia | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine allogeneic bone... peripheral bloo... radiation thera... | 18 Years - 55 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma | NCT00006747 | Graft Versus Ho... Lymphoma | carmustine melphalan etoposide cytarabine tacrolimus methotrexate sargramostim transplant | - 59 Years | Alliance for Clinical Trials in Oncology | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | NCT02500550 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | ATIR101 Haploidentical ... TBI regime Non-TBI regime | 18 Years - 65 Years | Kiadis Pharma | |
| Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis | NCT05158608 | Graft Versus Ho... Hematologic Mal... Cyclophosphamid... | Post-transplant... Post-transplant... | 18 Years - | National Research Center for Hematology, Russia | |
| Bone Marrow Transplantation in Treating Patients With Leukemia | NCT00006451 | Graft Versus Ho... Leukemia Lymphoma | anti-thymocyte ... cyclophosphamid... cyclosporine methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. | NCT02849886 | Graft Versus Ho... Hematological M... | T lymphocytes i... Dimerizer drug ... | 40 Years - 55 Years | Centre Hospitalier Universitaire de Besancon | |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | NCT00943293 | Preleukemia Myeloproliferat... Lymphoma Myeloma Graft Versus Ho... | Fludarabine Melphalan Campath | 18 Years - | University of Chicago | |
| Allogeneic Transplantation From Related Haploidentical Donors | NCT00185692 | Blood Cancer Leukemia Graft Versus Ho... Malignancy CLL NHL Hodgkin's Disea... MDS | non-myeloablati... Anti-Thymocyte ... Cyclosporine Mycophenolate M... G-CSF Solumedrol Acetaminophen Diphenydramine Hydrocortisone | 12 Months - | Stanford University | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC | |
| Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia | NCT00004878 | Graft Versus Ho... Leukemia | therapeutic all... cytarabine fludarabine pho... idarubicin methotrexate tacrolimus in vitro-treate... peripheral bloo... | 50 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease | NCT01174940 | Stem Cell Leuke... Graft Versus Ho... | extracorporeal ... | 18 Years - | University of Kansas Medical Center | |
| Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | NCT00002456 | Graft Versus Ho... Leukemia Lymphoma | cyclosporine methotrexate allogeneic bone... | - | Fred Hutchinson Cancer Center | |
| Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | NCT02188290 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | 18 Years - 65 Years | Kiadis Pharma | ||
| Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT00725062 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | CD4+CD25+ regul... allogeneic hema... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning | NCT00781781 | Graft Versus Ho... | Alemtuzumab | 40 Years - 65 Years | CABYC | |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | NCT03192397 | Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Chronic Myelomo... Graft Versus Ho... Hodgkin Lymphom... Minimal Residua... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Severe Aplastic... Waldenstrom Mac... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Hydro... Mycophenolate M... Sirolimus Total-Body Irra... | 18 Years - | Roswell Park Cancer Institute | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | NCT00577278 | Graft Versus Ho... Leukemia Lymphoma | rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom... | 18 Years - 69 Years | City of Hope Medical Center | |
| Open-Label Study Designed to Evaluate the Safety and Preliminary Efficacy of ApoCell for the Prevention of Acute GvHD | NCT00524784 | Graft Versus Ho... Hematological M... | ApoCell | 18 Years - 60 Years | Hadassah Medical Organization | |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis | NCT01749111 | Acute Myelogeno... Acute Lymphoid ... Myeloproliferat... Myelodysplastic... Chronic Myeloid... Chronic Myelomo... | ARM A Cyclophos... ARM B Calcineur... | 18 Years - 60 Years | Hospital Israelita Albert Einstein | |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. | NCT02849886 | Graft Versus Ho... Hematological M... | T lymphocytes i... Dimerizer drug ... | 40 Years - 55 Years | Centre Hospitalier Universitaire de Besancon | |
| Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | NCT00382109 | B-cell Childhoo... Childhood Acute... Graft Versus Ho... L1 Childhood Ac... L2 Childhood Ac... T-cell Childhoo... | thiotepa cyclophosphamid... tacrolimus methotrexate sirolimus total body irra... | 1 Year - 21 Years | Children's Oncology Group | |
| Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease | NCT06200441 | Acute Myeloid L... Graft Versus Ho... Endothelial Dys... | 18 Years - | Ankara University | ||
| T&B Depletion Non Malignant | NCT01810926 | Graft Versus Ho... | polyclonal anti... Rituximab Treosulfan Fludarabine Thiotepa Cyclosporine A Methotrexate Methotrexate | 28 Days - 64 Years | Bambino Gesù Hospital and Research Institute | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | NCT04361058 | Leukemia, Myelo... Myelodysplastic... Myelodysplastic... | Nivolumab | 18 Years - 65 Years | SCRI Development Innovations, LLC | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | NCT00003662 | Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera... | - | Roswell Park Cancer Institute | |
| IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms | NCT05111834 | Graft Vs Host D... | Supervised resi... Nutritional end... | 18 Years - | University Hospital Heidelberg | |
| Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | NCT01188798 | Acute Lymphobla... Acute Myelocyti... Chronic Myelocy... Hodgkin's Disea... Myelodysplastic... | Methotrexate Pentostatin | 18 Months - 21 Years | St. Jude Children's Research Hospital | |
| Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD | NCT06279585 | Graft-versus-ho... Graft Versus Ho... Stem Cell Trans... Hematological M... Hematologic Can... | Physical therap... | 18 Years - | University of Seville | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | NCT00144677 | Acute Myelogeno... Graft Versus Ho... Acute Lymphobla... Chronic Myeloge... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | sirolimus tacrolimus | 18 Years - 55 Years | Dana-Farber Cancer Institute | |
| Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease | NCT01174940 | Stem Cell Leuke... Graft Versus Ho... | extracorporeal ... | 18 Years - | University of Kansas Medical Center | |
| Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | NCT00376519 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo... | cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra... | 18 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | NCT01744223 | Acute Lymphobla... Acute Myelogeno... Lymphoma Myelodysplastic... | BPX-501 dose 1 Rimiducid BPX-501 dose 2 BPX-501 dose 3 BPX-501 dose 4 SCT | 18 Years - 65 Years | Bellicum Pharmaceuticals | |
| Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | NCT04361058 | Leukemia, Myelo... Myelodysplastic... Myelodysplastic... | Nivolumab | 18 Years - 65 Years | SCRI Development Innovations, LLC | |
| Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | NCT02188290 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... | 18 Years - 65 Years | Kiadis Pharma | ||
| Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | NCT04935684 | Acute Leukemia ... Myelodysplastic... Myeloproliferat... Hodgkin Lymphom... Lymphoma, Non-H... Myeloma Chronic Lymphoc... | Fecal Microbiot... | 18 Years - | University Hospital, Clermont-Ferrand | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways | NCT05124288 | Acute Myeloid L... | Observations on... | 18 Years - | IRCCS San Raffaele |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
